Epidemiology and survival of primary extraosseous plasmacytoma: insights from a population-based study with a 20-year follow-up

References

• Fend F, Dogan A, Cook JR. Plasma cell neoplasms and related entities-evolution in diagnosis and classification. Virchows Arch. 2023;482(1):163–177. doi:10.1007/s00428-022-03431-3
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi:10.1182/blood-2016-01-643569
   PubMed Web of Science ®Google Scholar
• Blade J, Fernandez de Larrea C, Rosinol L, et al. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011;29(28):3805–3812. doi:10.1200/JCO.2011.34.9290
   PubMed Web of Science ®Google Scholar
• Alexiou C, Kau RJ, Dietzfelbinger H, et al. Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer. 1999;85(11):2305–2314. doi:10.1002/(SICI)1097-0142(19990601)85:11<2305::AID-CNCR2>3.0.CO;2-3
   PubMed Web of Science ®Google Scholar
• Ellington TD, Henley SJ, Wilson RJ, et al. Trends in solitary plasmacytoma, extramedullary plasmacytoma, and plasma cell myeloma incidence and myeloma mortality by racial-ethnic group, United States 2003–2016. Cancer Med. 2021;10(1):386–395. doi:10.1002/cam4.3444
   PubMed Web of Science ®Google Scholar
• Holler A, Cicha I, Eckstein M, et al. Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts-a follow-up. Cancer Med. 2022;11(24):4743–4755. doi:10.1002/cam4.4816
   PubMed Web of Science ®Google Scholar
• Strojan P, Soba E, Lamovec J, et al. Extramedullary plasmacytoma: clinical and histopathologic study. Int J Radiat Oncol Biol Phys. 2002;53(3):692–701. doi:10.1016/s0360-3016(02)02780-3
   PubMed Web of Science ®Google Scholar
• Bink K, Haralambieva E, Kremer M, et al. Primary extramedullary plasmacytoma: similarities with and differences from multiple myeloma revealed by interphase cytogenetics. Haematologica. 2008;93(4):623–626. doi:10.3324/haematol.12005
   PubMed Web of Science ®Google Scholar
• Cavo M, Terpos E, Nanni C, et al. Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the international myeloma working group. Lancet Oncol. 2017;18(4):e206–e217. doi:10.1016/S1470-2045(17)30189-4
   PubMed Web of Science ®Google Scholar
• Soutar R, Lucraft H, Jackson G, et al. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol. 2004;124(6):717–726. doi:10.1111/j.1365-2141.2004.04834.x
   PubMed Web of Science ®Google Scholar
• Galieni P, Cavo M, Pulsoni A, et al. Clinical outcome of extramedullary plasmacytoma. Haematologica. 2000;85(1):47–51.
   PubMed Web of Science ®Google Scholar
• Barzenje DA, Kolstad A, Ghanima W, et al. Long-term outcome of patients with solitary plasmacytoma treated with radiotherapy: a population-based, single-center study with median follow-up of 13.7 years. Hematol Oncol. 2018;36(1):217–223. doi:10.1002/hon.2415
   PubMed Web of Science ®Google Scholar
• Guo SQ, Zhang L, Wang YF, et al. Prognostic factors associated with solitary plasmacytoma. Onco Targets Ther. 2013;6:1659–1666. doi:10.2147/OTT.S53248
   PubMed Web of Science ®Google Scholar
• Soesan M, Paccagnella A, Fau-Chiarion-Sileni V, et al. Extramedullary plasmacytoma: clinical behaviour and response to treatment. Ann Oncol. 1992;3:51–57.
   PubMed Web of Science ®Google Scholar
• Zhu X, Wang L, Zhu Y, et al. Extramedullary plasmacytoma: long-term clinical outcomes in a single-center in China and literature review. Ear Nose Throat J. 2021;100(4):227–232. doi:10.1177/0145561320950587
   PubMed Web of Science ®Google Scholar
• Shen X, Zhang L, Wang J, et al. Survival trends and prognostic factors for patients with extramedullary plasmacytoma: a population-based study. Front Oncol. 2022;12:1052903. doi:10.3389/fonc.2022.1052903
   PubMed Web of Science ®Google Scholar
• Nahi H, Genell A, Walinder G, et al. Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register. Eur J Haematol. 2017;99(3):216–222. doi:10.1111/ejh.12907
   PubMed Web of Science ®Google Scholar
• Alshomar KM, Altariqi SM, Alrikabi AC, et al. Primary extramedullary plasmacytoma of the eyelid conjunctiva – a case report and review of the literature. Ann Med Surg. 2020;55:1–4. doi:10.1016/j.amsu.2020.04.028
   PubMed Web of Science ®Google Scholar
• Group TIMW. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the international myeloma working group. Br J Haematol. 2003;121(5):749–757.
   PubMed Web of Science ®Google Scholar
• Naymagon L, Abdul-Hay M. Primary extramedullary plasmacytoma with diffuse lymph node involvement: a case report and review of the literature. J Med Case Rep. 2019;13(1):153.
   PubMedGoogle Scholar
• Gerry D, Lentsch EJ. Epidemiologic evidence of superior outcomes for extramedullary plasmacytoma of the head and neck. Otolaryngol Head Neck Surg. 2013;148(6):974–981. doi:10.1177/0194599813481334
   PubMedGoogle Scholar
• Ludwig H, Bolejack V, Crowley J, et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol. 2010;28(9):1599–1605. doi:10.1200/JCO.2009.25.2114
   PubMed Web of Science ®Google Scholar
• Thumallapally N, Meshref A, Mousa M, et al. Solitary plasmacytoma: population-based analysis of survival trends and effect of various treatment modalities in the USA. BMC Cancer. 2017;17(1):13. doi:10.1186/s12885-016-3015-5
   PubMed Web of Science ®Google Scholar
• Ghiassi-Nejad Z, Ru M, Moshier E, et al. Overall survival trends and clinical characteristics of plasmacytoma in the United States: a national cancer database analysis. Clin Lymphoma Myeloma Leuk. 2019;19(5):310–319. doi:10.1016/j.clml.2019.01.004
   PubMed Web of Science ®Google Scholar
• Aizer AA, Chen M-H, McCarthy EP, et al. Marital status and survival in patients with cancer. J Clin Oncol. 2013;31(31):3869–3876. doi:10.1200/JCO.2013.49.6489
   PubMed Web of Science ®Google Scholar
• Ding Z, Yu D, Li H, et al. Effects of marital status on overall and cancer-specific survival in laryngeal cancer patients: a population-based study. Sci Rep. 2021;11(1):723. doi:10.1038/s41598-020-80698-z
   PubMed Web of Science ®Google Scholar
• Kravdal Ø. The impact of marital status on cancer survival. Soc Sci Med. 2001;52(3):357–368. doi:10.1016/s0277-9536(00)00139-8
   PubMed Web of Science ®Google Scholar
• Glasbey JC, Arshad F, Almond LM, et al. Gastrointestinal manifestations of extramedullary plasmacytoma: a narrative review and illustrative case reports. Ann R Coll Surg Engl. 2018;100(5):371–376. doi:10.1308/rcsann.2018.0015
   PubMed Web of Science ®Google Scholar
• Pham A, Mahindra A. Solitary plasmacytoma: a review of diagnosis and management. Curr Hematol Malig Rep. 2019;14(2):63–69. doi:10.1007/s11899-019-00499-8
   PubMed Web of Science ®Google Scholar
• Finsinger P, Grammatico S, Chisini M, et al. Clinical features and prognostic factors in solitary plasmacytoma. Br J Haematol. 2016;172(4):554–560. doi:10.1111/bjh.13870
   PubMed Web of Science ®Google Scholar
• Tsang RW, Campbell BA, Goda JS, et al. Radiation therapy for solitary plasmacytoma and multiple myeloma: guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys. 2018;101(4):794–808. doi:10.1016/j.ijrobp.2018.05.009
   PubMed Web of Science ®Google Scholar
• Caers J, Paiva B, Zamagni E, et al. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. J Hematol Oncol. 2018;11(1):10. doi:10.1186/s13045-017-0549-1
   PubMed Web of Science ®Google Scholar
• Kilciksiz S, Karakoyun-Celik O, Agaoglu FY, et al. A review for solitary plasmacytoma of bone and extramedullary plasmacytoma. ScientificWorldJournal. 2012;2012:895765. doi:10.1100/2012/895765
   PubMedGoogle Scholar
• Iasonos A, Schrag D, Raj GV, et al. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364–1370. doi:10.1200/JCO.2007.12.9791
   PubMed Web of Science ®Google Scholar